Author

Guido A. Gualdoni

Sarepta Therapeutics (United States)ORCID 0000-0001-9490-0197Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:benchmarking· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

Anna-Dorothea GorkiiD· 1 shared Chama Najmi· 1 shared Delyana Stoeva· 1 shared Heta Telimaa· 1 shared Johannes StöckliD· 1 shared Laxmikant WaliiD· 1 shared Sarah K. WidemaniD· 1 shared Scharon Chou· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

Anna-Dorothea GorkiORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Nebulized 2-deoxylated glucose analogues inhibit respiratory viral infection in advanced in vitro airway models

Sarah K. Wideman, Laxmikant Wali, Vitalii Kovtunyk, Scharon Chou, Vanessa Gusel, Heta Telimaa, Chama Najmi, Delyana Stoeva, Johannes Stöckl, Guido A. Gualdoni, Anna-Dorothea Gorki, Snezana Radivojev

This study evaluates three 2-deoxylated glucose analogues for their antiviral and anti-inflammatory effects in advanced in vitro airway models, showing they inhibit respiratory viral replication and can be nebulized.

Scientific Reports · Mar 19, 2025Peer-reviewedMicrobiology